Apimeds Pharmaceuticals US (APUS) Income towards Parent Company (2024 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Income towards Parent Company came in at -$7.3 million in Q4 2025, down 1797.17% YoY from $429099.8 in Q4 2024, and down 305.91% on a QoQ basis from -$1.8 million in Q3 2025.
Apimeds Pharmaceuticals US (APUS) Income towards Parent Company (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 2 years of Income towards Parent Company data on file, last reported at -$7.3 million in Q4 2025.
- Quarterly Income towards Parent Company fell 1797.17% year-over-year to -$7.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$12.2 million (down 730.98% YoY) and the FY2025 annual result came in at -$14.5 million, down 498.81% from the prior year.
- Income towards Parent Company fell to -$7.3 million in Q4 2025, from -$1.8 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$296473.0 in Q1 2024 to a low of -$7.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Apimeds Pharmaceuticals US | 7.55 Mn | 7.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.28 Mn |
| Sep 30, 2025 | -1.79 Mn |
| Jun 30, 2025 | -2.67 Mn |
| Mar 31, 2025 | -402,397.00 |
| Dec 31, 2024 | -383,864.00 |
| Sep 30, 2024 | -332,521.00 |
| Jun 30, 2024 | -449,363.00 |
| Mar 31, 2024 | -296,473.00 |